Five people with spinal cord injuries have had microelectrode arrays implanted in the touch-processing region of their brains for as long as ten years — and, according to a study published July 15, 2026 in Science Translational Medicine, those implants are still safely restoring a working sense of touch. It is the longest-running human study yet of intracortical microstimulation (ICMS), the technique of delivering tiny electrical pulses directly into the brain’s somatosensory cortex to recreate the feeling of touch in a body region that can no longer send that signal on its own.
The trial, a collaboration between the University of Pittsburgh and the University of Chicago, is led by senior author Robert Gaunt, Ph.D. (Pitt) and lead author Charles M. Greenspon, Ph.D. (UChicago), with additional co-authors from UT Southwestern Medical Center. Across the five participants, the implanted arrays delivered more than 168 million stimulation pulses over a combined 27 years of cumulative implant time, with individual participants carrying their devices for between two and ten years, without a single serious adverse event attributed to the stimulation.
What the study found
When an electrode in the somatosensory cortex is stimulated, it produces a sensation the participant perceives as arising from a specific, localized patch of the hand — the same hand region that would normally send that signal before the injury interrupted it. The new paper’s central finding is durability: those localized sensations did not drift to different or diffuse body locations over years of repeated use, and roughly 64% of implanted electrodes remained functional on average across the cohort, with one participant retaining about 60% functional electrodes after a full decade. Detection thresholds — the minimum current needed to evoke a sensation — gradually rose over time, but stimulation remained reliably effective at evoking informative touch percepts throughout.
The researchers also tracked a rare side effect: on the order of 1 in every 23,000 stimulation trials produced a “persistent sensation” that outlasted the stimulation pulse itself, typically for under ten seconds, and none required medical intervention. Reporting this kind of rare-event, long-horizon safety data is only possible because the study ran as long as it did.
Why the decade-long duration is itself the finding
Most human trials of implanted neurotechnology report safety and performance over months, not years. A study spanning up to ten years in individual participants, with 27 cumulative implant-years across the cohort, is unusual by the standards of implanted-device research generally, not just brain-computer interface (BCI) work — and that duration is doing real evidentiary work here, not just extending a press release. Short-duration studies cannot show whether percept quality drifts, whether electrodes fail gradually or catastrophically, or whether rare adverse events (like the persistent-sensation trials above) are rare enough in practice to be acceptable, because those questions only resolve with years of continuous, repeated use.
That duration also raises the profile of the human-subjects dimension of this work. Five participants agreed to carry an implanted cortical device, and to return for repeated stimulation and testing sessions, for as long as a decade — which means informed consent in a study like this is not a single point-in-time event but something that has to remain meaningful across ten years of a participant’s life, alongside sustained institutional oversight of an active implant the whole time. Long-duration implanted-device trials like this one are one of the more direct ways the research enterprise actually generates the kind of long-term safety and efficacy evidence that shorter trials structurally cannot produce — at the cost of asking a comparatively small number of volunteers for an unusually sustained, multi-year commitment.
Dual funding: a civilian-defense research pipeline
The study’s funding acknowledgment names both the National Institutes of Health and the Defense Advanced Research Projects Agency (DARPA) as funders — a pairing that reflects how sensory-feedback BCI research sits at an intersection of civilian medical rehabilitation and defense-funded neurotechnology research. On the NIH side, the work draws on support administered in part through the NIH BRAIN Initiative alongside the National Institute of Neurological Disorders and Stroke, the National Eye Institute, and the National Institute on Drug Abuse (grants including UH3 NS107714, R35 NS122333, U01 NS108922, U01 NS123125, R01 NS130302, and R01 NS131953, per the University of Pittsburgh Medical Center’s release on the study). DARPA support is credited under contracts N66001-16-C-4051 and N66001-10-C-4056, reflecting the agency’s long-running interest — dating back to its Revolutionizing Prosthetics and Hand Proprioception and Touch Interfaces (HAPTIX) programs — in restoring sensory feedback for advanced prosthetic and neural-interface systems.
That dual-track funding is a useful reminder, for anyone tracking how translational neuroscience actually gets paid for, that a single clinical result can sit downstream of both a civilian biomedical research budget and a defense agency’s technology-development mandate at the same time, each with its own reporting and oversight requirements layered onto the same human-subjects protocol.
What comes next
The authors frame the result as evidence that ICMS-based sensory feedback is mature enough, from a safety standpoint, to support next-generation bidirectional BCIs — systems that would both record a user’s intended movement and deliver stimulated touch feedback back to the brain, closing the sensory loop for prosthetic or robotic-limb control in a way that open-loop motor-only systems cannot. The full study, its methods, and its complete author list are available via Science Translational Medicine (DOI: 10.1126/scitranslmed.aec3728); a plain-language summary is available from the University of Pittsburgh Medical Center.
Why this matters for research administration
For institutions running long-duration implanted-device or device-in-human trials, this study is a working example of what a decade-scale human-subjects protocol actually requires in practice: continuity of IRB oversight and consent across staff and personnel turnover, a plan for participants who may need to withdraw or whose device may need explantation years into a study, and funding structures — here spanning multiple NIH institutes and a defense-agency contract — that themselves have to be sustained, renewed, and reconciled across the same multi-year window as the clinical protocol itself.
